GlobalData on MSN8h
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
FierceBiotech12h
Intellia's CRISPR and Alnylam's RNAi data drops present contrasting visions for cardiomyopathy care
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
BioSpace10h
Intellia’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
Intellia Therapeutics Announces Promising CRISPR Therapy Results
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...
Intellia Therapeutics price target raised to $91 from $88 at Chardan
Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company ...
STAT9h
Novartis ramps up in radiopharma, and Eli Lilly adds Zepbound details
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
FierceBiotech4h
Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis
As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM), the company has presented more ...
Armed robbery in Revesby5h
OHSU Trials CRISPR for Fatal Heart Condition
Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...
Le Lézard10h
Dantech Returns to AWS re:Invent 2024 to Celebrate 7 Years of Client-Centric Cloud Innovation and Success
Dantech Corporation, an AWS partner since 2017, will join other industry leaders at AWS re:Invent 2024, taking place between December 2-6 at the Venetian in Las Vegas. Dantech will also be celebrating ...
Le Lézard10h
Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular malformations, today announces that the US Food and Drug ...
marketinference3h
Intellia Therapeutics – Positive Phase 1 Data for Nexiguran Ziclumeran in ATTR-CM
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has released positive new clinical data from the ongoing phase 1 trial of Nexiguran Ziclumeran (Nex-Z), also known as NTLA-2001, in patients with ...